This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To determine if autologous peripheral T lymphocytes reactive to myelin proteins when injected back into the patient will stop the progression of the disease. This is a Phase II randomized double-blind study of 80 patients (40x2). The primary outcome is MRI and secondary outcome measurements are clinical and immunological. This is a three-year study with two years of vaccination and one year follow-up.
Showing the most recent 10 out of 565 publications